[{"address1": "1800 Kraft Drive", "address2": "Suite 216", "city": "Blacksburg", "state": "VA", "zip": "24060", "country": "United States", "phone": "540 218 1767", "website": "https://landosbiopharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate is NX-13, an oral gut-selective Nucleotide Oligomerization Domain (NLRX1), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines that completed Phase Ib clinical trial to treat ulcerative colitis (UC), as well as induce anti-inflammatory effects in CD4+ T cells and other cells in the gastrointestinal tract. The company's preclinical candidates in development include LABP-73, an oral and small molecule NLRX1 pathway agonist in development for the treatment of asthma and chronic obstructive pulmonary disease; LABP-66 is an oral and small molecule NLRX1 pathway agonist for the treatment of multiple sclerosis and Alzheimer's disease; and LABP-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and RA. The company has a strategic research collaboration with KU Leuven and University Hospitals Leuven to investigate the effects of NX-13 on epithelial cells with the inflammatory bowel disease. The company was incorporated in 2017 and is headquartered in Blacksburg, Virginia.", "fullTimeEmployees": 19, "companyOfficers": [{"maxAge": 1, "name": "Mr. Gregory  Oakes", "age": 55, "title": "President, CEO & Director", "yearBorn": 1968, "fiscalYear": 2022, "totalPay": 1035787, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Fabio  Cataldi M.D.", "age": 56, "title": "Executive VP & Chief Medical Officer", "yearBorn": 1967, "fiscalYear": 2022, "totalPay": 516679, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jennifer  Creel", "age": 52, "title": "Interim Chief Financial Officer", "yearBorn": 1971, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Rebecca  Mosig Ph.D.", "title": "Vice President of Corporate Development", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Josep  Bassaganya-Riera DVM, Ph.D.", "age": 48, "title": "Advisor", "yearBorn": 1975, "fiscalYear": 2022, "totalPay": 1788694, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 8, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1711929600, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 2, "previousClose": 21.5, "open": 21.54, "dayLow": 21.43, "dayHigh": 21.57, "regularMarketPreviousClose": 21.5, "regularMarketOpen": 21.54, "regularMarketDayLow": 21.43, "regularMarketDayHigh": 21.57, "beta": 0.152, "forwardPE": -12.839286, "volume": 18625, "regularMarketVolume": 18625, "averageVolume": 25601, "averageVolume10days": 25200, "averageDailyVolume10Day": 25200, "marketCap": 67227864, "fiftyTwoWeekLow": 2.5, "fiftyTwoWeekHigh": 21.87, "fiftyDayAverage": 10.74764, "twoHundredDayAverage": 5.71035, "currency": "USD", "enterpriseValue": 29728844, "floatShares": 1320652, "sharesOutstanding": 3116730, "sharesShort": 4900, "sharesShortPriorMonth": 1137, "sharesShortPreviousMonthDate": 1709164800, "dateShortInterest": 1711584000, "sharesPercentSharesOut": 0.0016, "heldPercentInsiders": 0.09917, "heldPercentInstitutions": 0.48958, "shortRatio": 0.11, "shortPercentOfFloat": 0.003, "impliedSharesOutstanding": 3116730, "bookValue": 10.2, "priceToBook": 2.1147058, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -21935000, "trailingEps": -3.5, "forwardEps": -1.68, "lastSplitFactor": "1:10", "lastSplitDate": 1685059200, "enterpriseToEbitda": -1.342, "52WeekChange": 6.19, "SandP52WeekChange": 0.21828604, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "LABP", "underlyingSymbol": "LABP", "shortName": "Landos Biopharma, Inc.", "longName": "Landos Biopharma, Inc.", "firstTradeDateEpochUtc": 1612449000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "8d3ef42b-743e-3c42-a8bb-b248f7b0945c", "messageBoardId": "finmb_432438570", "gmtOffSetMilliseconds": -14400000, "currentPrice": 21.57, "targetHighPrice": 20.42, "targetLowPrice": 5.0, "targetMeanPrice": 12.71, "targetMedianPrice": 12.71, "recommendationMean": 3.0, "recommendationKey": "hold", "numberOfAnalystOpinions": 2, "totalCash": 37499000, "totalCashPerShare": 12.032, "ebitda": -22150000, "quickRatio": 6.001, "currentRatio": 6.087, "returnOnAssets": -0.34107, "returnOnEquity": -0.61856997, "freeCashflow": -12796375, "operatingCashflow": -20477000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-04-16"}]